BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6251
- TODAY'S CHANGE (%)-0.0049 (-0.7778%)
- Bid / Lots0.6251/ 1
- Ask / Lots0.6302/ 6
- Open / Previous Close0.6270 / 0.6300
- Day Range
- 52 Week Range
- Volume126,145
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 649 | 0.63 |
| 09:39 ET | 500 | 0.635 |
| 09:52 ET | 27922 | 0.64 |
| 09:54 ET | 4567 | 0.63 |
| 09:56 ET | 1400 | 0.6268 |
| 09:57 ET | 4000 | 0.625 |
| 09:59 ET | 3900 | 0.6251 |
| 10:01 ET | 4000 | 0.6263 |
| 10:03 ET | 6655 | 0.64 |
| 10:14 ET | 1000 | 0.65 |
| 10:19 ET | 1110 | 0.65 |
| 10:21 ET | 123 | 0.64 |
| 10:26 ET | 2550 | 0.64 |
| 10:44 ET | 198 | 0.65 |
| 10:48 ET | 200 | 0.6402 |
| 10:51 ET | 2700 | 0.64 |
| 10:53 ET | 1825 | 0.6326 |
| 10:55 ET | 1010 | 0.632599 |
| 10:57 ET | 600 | 0.6396 |
| 11:00 ET | 1000 | 0.632801 |
| 11:02 ET | 1198 | 0.6327 |
| 11:09 ET | 8000 | 0.631401 |
| 11:11 ET | 2359 | 0.631401 |
| 11:13 ET | 3698 | 0.6302 |
| 11:31 ET | 2000 | 0.631441 |
| 11:38 ET | 1790 | 0.6302 |
| 11:54 ET | 100 | 0.6301 |
| 11:58 ET | 9200 | 0.6302 |
| 12:07 ET | 999 | 0.6302 |
| 12:09 ET | 2150 | 0.6302 |
| 12:12 ET | 2000 | 0.6301 |
| 12:14 ET | 100 | 0.6301 |
| 12:18 ET | 165 | 0.6301 |
| 12:20 ET | 14452 | 0.6251 |
| 12:21 ET | 10112 | 0.6251 |
Sep 17, 2024
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection, from 1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 4, 2024
DJ BioLine RX Initiated at Buy by Jones Trading, from 12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 53.6M | -0.8x | --- |
Kronos Bio Inc | 57.6M | -0.6x | --- |
Adlai Nortye Ltd | 72.7M | -0.3x | --- |
LAVA Therapeutics NV | 43.4M | -1.9x | --- |
Omega Therapeutics Inc | 69.5M | -0.9x | --- |
Singular Genomics Systems Inc | 38.7M | -0.4x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $53.6M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
